CN103834721A - 一种细胞色素p450 cyp3a4 snp的检测试剂盒 - Google Patents
一种细胞色素p450 cyp3a4 snp的检测试剂盒 Download PDFInfo
- Publication number
- CN103834721A CN103834721A CN201310054334.2A CN201310054334A CN103834721A CN 103834721 A CN103834721 A CN 103834721A CN 201310054334 A CN201310054334 A CN 201310054334A CN 103834721 A CN103834721 A CN 103834721A
- Authority
- CN
- China
- Prior art keywords
- probe
- microlitre
- mix
- adsorption column
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 title claims abstract description 7
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 title claims abstract description 7
- 239000002773 nucleotide Substances 0.000 title abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 title abstract description 9
- 102000054765 polymorphisms of proteins Human genes 0.000 title abstract description 4
- 239000000523 sample Substances 0.000 claims abstract description 45
- 238000001179 sorption measurement Methods 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 9
- 239000002699 waste material Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000005662 Paraffin oil Substances 0.000 claims description 7
- 238000002242 deionisation method Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 5
- 239000012149 elution buffer Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000013615 primer Substances 0.000 claims description 3
- 239000002987 primer (paints) Substances 0.000 claims description 3
- 235000019833 protease Nutrition 0.000 claims description 3
- 238000001190 Q-PCR Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 21
- 229960001549 ropivacaine Drugs 0.000 description 21
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 21
- 229960004739 sufentanil Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 230000036407 pain Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 9
- 229960002428 fentanyl Drugs 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 230000036592 analgesia Effects 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000032696 parturition Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000036267 drug metabolism Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 101150116544 CYP3A4 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310054334.2A CN103834721B (zh) | 2013-02-20 | 2013-02-20 | 一种细胞色素p450 cyp3a4 snp的检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310054334.2A CN103834721B (zh) | 2013-02-20 | 2013-02-20 | 一种细胞色素p450 cyp3a4 snp的检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103834721A true CN103834721A (zh) | 2014-06-04 |
CN103834721B CN103834721B (zh) | 2016-03-09 |
Family
ID=50798615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310054334.2A Active CN103834721B (zh) | 2013-02-20 | 2013-02-20 | 一种细胞色素p450 cyp3a4 snp的检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103834721B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107354213A (zh) * | 2017-07-05 | 2017-11-17 | 华中科技大学同济医学院附属同济医院 | 检测疼痛相关基因的基因芯片及检测试剂盒 |
CN107893114A (zh) * | 2017-12-29 | 2018-04-10 | 韩林志 | 用于指导芬太尼类药物个体化用药相关基因检测的引物对、试剂盒及方法 |
CN109913540A (zh) * | 2017-12-12 | 2019-06-21 | 上海奥马生物科技有限公司 | 一种检测cyp3a多态性位点的试剂盒及其用途 |
CN112553325A (zh) * | 2020-12-29 | 2021-03-26 | 广东南芯医疗科技有限公司 | 舒芬太尼个体化用药基因的指导方法及试剂盒 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007103977A2 (en) * | 2006-03-08 | 2007-09-13 | Genomas, Inc. | A physiogenomic method for predicting clinical outcomes of treatments in patients |
JP4305609B2 (ja) * | 2002-04-23 | 2009-07-29 | 国立医薬品食品衛生研究所長 | 薬剤代謝へ影響を及ぼすcyp3a4遺伝子多型、およびその利用 |
US20110159479A1 (en) * | 2009-12-28 | 2011-06-30 | Industry-University Cooperation Foundation Yonsei University | Genetic polymorphisms in the cytochrome p450 gene with clopidogrel resistance |
CN102277443A (zh) * | 2011-09-16 | 2011-12-14 | 协和干细胞基因工程有限公司 | 检测他克莫司和环孢素a个体化用药相关snp位点的试剂盒及扩增方法和检测方法 |
CN102307895A (zh) * | 2008-12-04 | 2012-01-04 | 里兰斯坦福初级大学理事会 | 用于治疗或预防麻醉药停药症状的方法和组合物 |
-
2013
- 2013-02-20 CN CN201310054334.2A patent/CN103834721B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4305609B2 (ja) * | 2002-04-23 | 2009-07-29 | 国立医薬品食品衛生研究所長 | 薬剤代謝へ影響を及ぼすcyp3a4遺伝子多型、およびその利用 |
WO2007103977A2 (en) * | 2006-03-08 | 2007-09-13 | Genomas, Inc. | A physiogenomic method for predicting clinical outcomes of treatments in patients |
CN102307895A (zh) * | 2008-12-04 | 2012-01-04 | 里兰斯坦福初级大学理事会 | 用于治疗或预防麻醉药停药症状的方法和组合物 |
US20110159479A1 (en) * | 2009-12-28 | 2011-06-30 | Industry-University Cooperation Foundation Yonsei University | Genetic polymorphisms in the cytochrome p450 gene with clopidogrel resistance |
CN102277443A (zh) * | 2011-09-16 | 2011-12-14 | 协和干细胞基因工程有限公司 | 检测他克莫司和环孢素a个体化用药相关snp位点的试剂盒及扩增方法和检测方法 |
Non-Patent Citations (2)
Title |
---|
YUTAKA ODA M.D.等: "Metabolism of a New Local Anesthetic, Ropivacaine, by Human Hepatic Cytochrome P450", 《ANESTHESIOLOGY》 * |
董章利: "汉族人细胞色素酶P450 3A4基因SNP rs2242480对经腹子宫全切除术汉族患者术后芬太尼静脉镇痛用量的影响", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107354213A (zh) * | 2017-07-05 | 2017-11-17 | 华中科技大学同济医学院附属同济医院 | 检测疼痛相关基因的基因芯片及检测试剂盒 |
CN109913540A (zh) * | 2017-12-12 | 2019-06-21 | 上海奥马生物科技有限公司 | 一种检测cyp3a多态性位点的试剂盒及其用途 |
CN107893114A (zh) * | 2017-12-29 | 2018-04-10 | 韩林志 | 用于指导芬太尼类药物个体化用药相关基因检测的引物对、试剂盒及方法 |
CN112553325A (zh) * | 2020-12-29 | 2021-03-26 | 广东南芯医疗科技有限公司 | 舒芬太尼个体化用药基因的指导方法及试剂盒 |
CN112553325B (zh) * | 2020-12-29 | 2024-08-13 | 广东南芯医疗科技有限公司 | 舒芬太尼个体化用药基因的指导方法及试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN103834721B (zh) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tzvetkov et al. | Increased systemic exposure and stronger cardiovascular and metabolic adverse reactions to fenoterol in individuals with heritable OCT1 deficiency | |
EP3854403A1 (en) | Use of substituted aminopropionate compounds in treatment of sars-cov-2 infection | |
Fukuda et al. | Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery | |
Chou et al. | Association of μ‐opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty | |
Barr et al. | Association of a functional polymorphism in the μ-opioid receptor gene with alcohol response and consumption in male rhesus macaques | |
Klimscha et al. | Intrathecal α2-adrenergic agonists stimulate acetylcholine and norepinephrine release from the spinal cord dorsal horn in sheep: An in vivo microdialysis study | |
Peart et al. | Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors | |
Belcher et al. | Bisphenol A alters autonomic tone and extracellular matrix structure and induces sex-specific effects on cardiovascular function in male and female CD-1 mice | |
CN102586408B (zh) | 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒 | |
JP2021116296A (ja) | コロナウイルス感染の治療におけるファビピラビルの使用 | |
Zhang et al. | Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women | |
CN103834721B (zh) | 一种细胞色素p450 cyp3a4 snp的检测试剂盒 | |
van Dijk et al. | The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm | |
Schütte et al. | Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs | |
CN101892311A (zh) | 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒 | |
CN107922947A (zh) | 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂 | |
KR20050085966A (ko) | 레닌-안지오텐신계 억제제의 용도 | |
JP6894155B2 (ja) | 特定の遺伝子マーカーを有する患者に用いるがん治療用の医薬組成物 | |
Aslibekyan et al. | Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network | |
Ginosar et al. | Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic–pharmacodynamic study | |
Ginosar et al. | Duration of analgesia and pruritus following intrathecal fentanyl for labour analgesia: no significant effect of A118G μ-opioid receptor polymorphism, but a marked effect of ethnically distinct hospital populations | |
Hesse et al. | β2‐Adrenoceptor gene variation and systemic vasodilatation during ganglionic blockade | |
CN103468812B (zh) | 一种检测糖皮质激素治疗sle疗效的试剂盒 | |
WO2021145871A1 (en) | A method of treatment in predisposed subjects for lmna-related dilated cardiomyopathy | |
CN103122376B (zh) | 一种rs6311的检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING UNIV. Free format text: FORMER OWNER: E WEN Effective date: 20140812 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140812 Address after: 100191 Department of Pathology, Peking University Health Science Center, Beijing, Haidian District Applicant after: Peking University Address before: 100191 pathology building, Peking University Health Science Center, Beijing, Haidian District 216 Applicant before: E Wen |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Chi Liqun Inventor after: Tian Xinxia Inventor after: Zhang Xiaojing Inventor after: Feng Yi Inventor after: Xu Mingjun Inventor after: An Haiyan Inventor after: Zhang Qinglin Inventor after: Huang Zhenyu Inventor after: Lu Xin Inventor after: E Wen Inventor before: Chi Liqun Inventor before: Zhang Xiaojing Inventor before: E Wen Inventor before: Shao Hong Inventor before: Liu Shuping Inventor before: Lu Xin |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190614 Address after: 100191 Second Floor B204, Building 1, 44 Huayuan North Road, Haidian District, Beijing Patentee after: Beijing able Ankang Biological Technology Co., Ltd. Address before: 100191 Department of Pathology, Peking University Medical Department, Haidian District, Beijing Patentee before: Peking University |